Hirokazu Nishino

944 total citations
19 papers, 777 citations indexed

About

Hirokazu Nishino is a scholar working on Oncology, Surgery and Hepatology. According to data from OpenAlex, Hirokazu Nishino has authored 19 papers receiving a total of 777 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 7 papers in Surgery and 7 papers in Hepatology. Recurrent topics in Hirokazu Nishino's work include Inflammatory Biomarkers in Disease Prognosis (7 papers), Hepatocellular Carcinoma Treatment and Prognosis (7 papers) and Cancer, Lipids, and Metabolism (7 papers). Hirokazu Nishino is often cited by papers focused on Inflammatory Biomarkers in Disease Prognosis (7 papers), Hepatocellular Carcinoma Treatment and Prognosis (7 papers) and Cancer, Lipids, and Metabolism (7 papers). Hirokazu Nishino collaborates with scholars based in Japan and United States. Hirokazu Nishino's co-authors include Akiyoshi Kinoshita, Hiroshi Onoda, Nami Imai, Nao Fushiya, Kazuhiko Koike, Akira Iwaku, Masato Matsushima, Ken Tanaka, Mutumi Oishi and Hisao Tajiri and has published in prestigious journals such as Gastroenterology, American Journal of Physiology-Gastrointestinal and Liver Physiology and Annals of Surgical Oncology.

In The Last Decade

Hirokazu Nishino

18 papers receiving 764 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Hirokazu Nishino Japan 10 481 280 185 183 175 19 777
Renata D’Alpino Peixoto Brazil 17 569 1.2× 295 1.1× 164 0.9× 320 1.7× 36 0.2× 95 964
Campbell SD Roxburgh United Kingdom 8 797 1.7× 270 1.0× 237 1.3× 230 1.3× 44 0.3× 22 924
Tetsuro Tominaga Japan 17 502 1.0× 322 1.1× 96 0.5× 192 1.0× 54 0.3× 114 737
Junji Kita Japan 15 330 0.7× 293 1.0× 126 0.7× 193 1.1× 221 1.3× 37 663
A. Khan United Kingdom 17 621 1.3× 475 1.7× 130 0.7× 307 1.7× 423 2.4× 47 1.0k
Tetsuro Ikeya Japan 12 479 1.0× 172 0.6× 178 1.0× 111 0.6× 30 0.2× 20 640
Xianchun Meng China 10 308 0.6× 90 0.3× 208 1.1× 88 0.5× 53 0.3× 14 726
Taflan Salepçi Türkiye 16 372 0.8× 271 1.0× 84 0.5× 221 1.2× 38 0.2× 40 803
Xin An China 15 839 1.7× 423 1.5× 201 1.1× 183 1.0× 42 0.2× 29 1.0k
Dianrong Xiu China 19 525 1.1× 325 1.2× 106 0.6× 245 1.3× 125 0.7× 98 944

Countries citing papers authored by Hirokazu Nishino

Since Specialization
Citations

This map shows the geographic impact of Hirokazu Nishino's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hirokazu Nishino with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hirokazu Nishino more than expected).

Fields of papers citing papers by Hirokazu Nishino

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hirokazu Nishino. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hirokazu Nishino. The network helps show where Hirokazu Nishino may publish in the future.

Co-authorship network of co-authors of Hirokazu Nishino

This figure shows the co-authorship network connecting the top 25 collaborators of Hirokazu Nishino. A scholar is included among the top collaborators of Hirokazu Nishino based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hirokazu Nishino. Hirokazu Nishino is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Kinoshita, Akiyoshi, Kazuhiko Koike, & Hirokazu Nishino. (2016). Clinical features and prognosis of elderly patients with hepatocellular carcinoma not indicated for surgical resection. Geriatrics and gerontology international. 17(2). 189–201. 24 indexed citations
2.
Kinoshita, Akiyoshi, et al.. (2016). [A Case of Primary Cancer of the Pancreas and Colon Treated with the Combination of Gemcitabine and TS-1].. PubMed. 43(3). 369–71.
3.
Kinoshita, Akiyoshi, Noriko Hagiwara, Takeharu Yokota, et al.. (2016). A case of adenosquamous cell carcinoma of the gallbladder with markedly elevated PTHrP and G-CSF levels.. PubMed. 113(9). 1564–71. 5 indexed citations
4.
Kinoshita, Akiyoshi, Hiroshi Onoda, Kaoru Ueda, et al.. (2015). Clinical characteristics and survival outcomes of super‐elderly hepatocellular carcinoma patients not indicated for surgical resection. Hepatology Research. 46(3). 6 indexed citations
5.
Kinoshita, Akiyoshi, Hiroshi Onoda, Nami Imai, Hirokazu Nishino, & Hisao Tajiri. (2015). C-Reactive Protein as a Prognostic Marker in Patients with Hepatocellular Carcinoma.. PubMed. 62(140). 966–70. 35 indexed citations
6.
Kinoshita, Akiyoshi & Hirokazu Nishino. (2014). IL-6, A Promising Tumor Marker and Prognostic Indicator in Patients with HCC?. 2(6). 142–144. 1 indexed citations
7.
Kinoshita, Akiyoshi, Hiroshi Onoda, Nami Imai, et al.. (2014). The Addition of C-Reactive Protein to Validated Staging Systems Improves Their Prognostic Ability in Patients with Hepatocellular Carcinoma. Oncology. 86(5-6). 308–317. 13 indexed citations
8.
Kinoshita, Akiyoshi, Hiroshi Onoda, Nami Imai, et al.. (2014). The C-Reactive Protein/Albumin Ratio, a Novel Inflammation-Based Prognostic Score, Predicts Outcomes in Patients with Hepatocellular Carcinoma. Annals of Surgical Oncology. 22(3). 803–810. 364 indexed citations
9.
Kinoshita, Akiyoshi, Hiroshi Onoda, Nami Imai, et al.. (2013). Elevated Plasma Fibrinogen Levels Are Associated with a Poor Prognosis in Patients with Hepatocellular Carcinoma. Oncology. 85(5). 269–277. 50 indexed citations
10.
Iwaku, Akira, Akiyoshi Kinoshita, Hiroshi Onoda, et al.. (2013). The Glasgow Prognostic Score accurately predicts survival in patients with biliary tract cancer not indicated for surgical resection. Medical Oncology. 31(1). 787–787. 19 indexed citations
11.
Fushiya, Nao, et al.. (2013). Genetic polymorphisms of enzymes related to oral tegafur/uracil therapeutic efficacy in patients with hepatocellular carcinoma. Anti-Cancer Drugs. 24(6). 617–622. 4 indexed citations
12.
Kinoshita, Akiyoshi, Hiroshi Onoda, Nami Imai, et al.. (2013). The Glasgow Prognostic Score, an inflammation based prognostic score, predicts survival in patients with hepatocellular carcinoma. BMC Cancer. 13(1). 92 indexed citations
13.
Kinoshita, Akiyoshi, Hiroshi Onoda, Keiko Takano, et al.. (2012). Pretreatment serum C-reactive protein level predicts poor prognosis in patients with hepatocellular carcinoma. Medical Oncology. 29(4). 2800–2808. 55 indexed citations
14.
Kinoshita, Akiyoshi, Yoshihiko Aoki, Shigeo Tamaki, et al.. (2008). [Case of lymphangioleiomyomatosis associated with protein-losing gastroenteropathy].. PubMed. 105(12). 1775–80. 3 indexed citations
15.
Koyama, Yu, et al.. (2007). Dynamics of Aquaporin 1 and Aquaporin 8 in the Pancreas : An Experimental Study with a Caerulein-induced Pancreatitis Model. 55(4). 91–101. 2 indexed citations
16.
Nishino, Hirokazu. (2006). [High risk factors for bile duct cancer].. PubMed. 64 Suppl 1. 439–42. 1 indexed citations
17.
Nishino, Hirokazu & Gotaro Toda. (2004). [Role of immunological disorders in the pathophysiology of severe acute pancreatitis].. PubMed. 62(11). 2009–14. 2 indexed citations
18.
Nishino, Hirokazu, Yasuhiro Tsunoda, & Chung Owyang. (1998). Mammalian bombesin receptors are coupled to multiple signal transduction pathways in pancreatic acini. American Journal of Physiology-Gastrointestinal and Liver Physiology. 274(3). G525–G534. 31 indexed citations
19.
Rünzi, Michael, Ashok K. Saluja, Markus M. Lerch, et al.. (1993). Early ductal decompression prevents the progression of biliary pancreatitis: An experimental study in the opossum. Gastroenterology. 105(1). 157–164. 70 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Renata D’Alpino Peixoto Breakdown of academic impact, for papers by Campbell SD Roxburgh Breakdown of academic impact, for papers by Tetsuro Tominaga Breakdown of academic impact, for papers by Junji Kita Breakdown of academic impact, for papers by A. Khan Breakdown of academic impact, for papers by Tetsuro Ikeya Breakdown of academic impact, for papers by Xianchun Meng Breakdown of academic impact, for papers by Taflan Salepçi Breakdown of academic impact, for papers by Xin An Breakdown of academic impact, for papers by Dianrong Xiu
Rankless by CCL
2026